24/7 Market News Snapshot 11 December, 2024 – 60 Degrees Pharmaceuticals, Inc. Common Stock (NASDAQ:SXTP)

December 11, 2024

DENVER, Colo., 11 December, 2024 (247marketnews.com) – (NASDAQ:SXTP) are discussed in this article.
60 Degrees Pharmaceuticals, Inc. (SXTP) has commenced trading with a notable upward movement, currently reflecting a 19.59% increase to $2.33, following an earlier session close at $1.95. With a trading volume exceeding 1.04 million shares, the substantial investor engagement may indicate a strong bullish momentum. Analysts suggest that maintaining this trend could be contingent upon overcoming key resistance levels, making it crucial for investors to observe both volume and price behavior for signs of sustainability or retracement in the forthcoming period.

In a significant development, the company has also launched a pivotal clinical trial aimed at assessing the safety and efficacy of tafenoquine for patients suffering from severe babesiosis, a serious tick-borne illness particularly threatening to the elderly and immunocompromised populations. This innovative study, in partnership with renowned researchers at Brigham and Women’s Hospital, targets an urgent unmet need in the domain of infectious disease treatment.

Designated NCT06207370, the trial will employ a double-blind, placebo-controlled methodology involving hospitalized patients. Participants will receive tafenoquine alongside standard treatment protocols, potentially introducing a transformative therapy for this severe condition. The study will extend to various prestigious locations, including Tufts Medical Center and Yale University, illustrating a robust academic collaboration.

The primary endpoints will measure the duration until sustained clinical resolution of symptoms and the time required for molecular cure, verified through FDA-sanctioned nucleic acid testing. Recruitment is set to initiate in the summer of 2025, with preliminary analysis scheduled for early 2026, highlighting the company’s focus on advancing therapeutic solutions.

Geoffrey Dow, PhD, CEO and President of 60 Degrees Pharmaceuticals, expressed optimism regarding this collaboration, emphasizing the alignment of the trial with the company’s mission to enhance patient care in severe babesiosis. Given the rising global incidence of this disease, outcomes from the trial could greatly benefit affected individuals, showcasing the company’s dedication to tackling infectious disease challenges.

Related news for (SXTP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.